ABSTRACT

The present disclosure relates to an mRNA tumor vaccine encoding a membrane-tethered IL-12 cytokine adjuvant and uses thereof, which reduces IL-12 toxicity and improves the therapeutic efficacy of the mRNA tumor vaccine. The mRNA comprises three components: an IL-12-encoding sequence (IL12), a membrane-domain-encoding sequence (MD), and a tumor-antigen-encoding sequence (Ag).

Fig. 5